The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.

Bristol Myers Squibb received good news from the FDA, but only enough to put a key resistance level in play. Here's the level it needs to clear.

Stocks finished higher after snapping a three-week losing streak as the dollar continues to slide against its global currency peers.

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

Competitive drug prices are great for consumers. Turns out, they're good for industry, too.

U.S. stocks finished the session higher, reversing two consecutive days of losses, as investors looked past Pelosi's Taiwan visit and ahead to key economic data.

Stocks close lower as House Speaker Nancy Pelosi's landing in Taiwan stokes geopolitical concern.

Investors await second-quarter earnings results from Pinterest, Activision Blizzard, Starbucks, Caterpillar and more for more signs of whether the Fed’s inflation battle is working.

It has one product on the market and up to four more launching by the end of 2023. The growth trajectory depends on execution.

Fully 89% of Americans say ex-offenders should be given a second chance, a survey says.

Participation in this sport grew the fastest of any in the U.S. from 2019-21, reaching the 4.8 million-player mark.

DocuSign said the job cuts will "improve operating margin and support the company’s growth, scale and profitability objectives".